Stem cell exosomes are small vesicles ranging from 30-100nm in size that are secreted by all stem cell types. They facilitate a range of important cellular functions. As the market for stem cell exosomes has emerged, a number of investment groups have made bets on this rapidly growing marketplace.
Venture Capital Supporting Exosome Diagnostics and Therapeutics
- Forbion Capital Partner
- NGN Capital, Arcus Ventures
- Tiger Management
- Blue Ridge Capital
- CD Ventures
It is interesting to see Qiagen on the list of investors, because Exosome Diagnostics and QIAGEN N.V. signed a July 2013 partnership to “develop and commercialize high-performance, co-branded kit products for the capture and processing of RNA and DNA from biofluid exosomes and other microvesicles.”
In January 2014, Exosome Diagnostics announced “expansion of their strategic collaboration with QIAGEN to develop non-invasive molecular diagnostics for use in detecting and monitoring actionable genetic mutations in lung cancer patients.” This investment indicates that Exosome Diagnostics and Qiagen are not only product development partners, but that Qiagen is also a stakeholder in Exosome Diagnostics.
On July 24, 2017, Exosome Diagnostics then closed $30 million in Series C financing, led by insiders, Tiger Partners and Forbion Capital Partners, while Blue Ridge Capital, NGN Capital, Arcus Ventures, b-to-v Partners, CD Ventures and others participated in the round.
Additionally, Codiak Biosciences was launched in late 2016 when the University of Texas MD Anderson Cancer Center joined two venture capital firms (ARCH Venture Partners and Flagship Ventures) and co-founder Eric Lander, Ph.D, to launch the company with more than $80 million in Series A and B financing. Codiak is using the funding to aggressively purpose the development of exosomes for therapeutic and diagnostic purposes, with an emphasis on cancer-related applications.
Investors in Codiak’s initial $80+ million Series A and Series B funding syndicate included:
- ARCH Venture Partners and Flagship Ventures (co-lead founding investors)
- Fidelity Management and Research Company
- Alaska Permanent Fund
- Alexandria Venture Investments
Flagship’s VentureLabs® innovation unit has worked since last 2015 to apply exosomes as a therapeutic platform, producing an intellectual property (IP) portfolio consisting of “patents held by one of its startups, VentureLabs Newco VL27—which merged into Codiak after acquiring exosome-related IP work of an advisor to the company, Jan Lotvall, M.D., Ph.D.”
Finally, ExCoBio, Inc., announced in May 2017 that it had raised US $11 million in a Series A funding round within four months of its being founded, making it the “largest and fastest investment attraction in South Korea”. The investment was secured from South Korean venture capital firms, including:
- SBI Investment
- Atinum Investment
- ID Ventures
Since being founded in January 2017, ExoCoBio raised a total of US $13.5 million and is planning to establish research and development (R&D) and GMP facilities to commercialize exosome-based cosmeceuticals and biopharmaceuticals that utilize stem cell-derived exosomes.
Clearly, investment firms are becoming increasingly interested in stem cell exosomes, making this an interesting market to watch.
To learn more, view the 134-page global strategic report, “The Market for Stem Cell Exosomes.”
 Exosomedx.com. (2017). Investors | Exosome Diagnostics. [online] Available at: http://www.exosomedx.com/investors [Accessed 28 Aug. 2017].
 Press Releases | Exosome Diagnostics. [online] Available at: http://www.exosomedx.com/news-events/press-releases/exosome-diagnostics-and-qiagen-partner-launch-comprehensive-line-biofluid [Accessed 31 Aug. 2017].
 Exosomedx.com. (2017). Press Releases | Exosome Diagnostics. [online] Available at: http://www.exosomedx.com/news-events/press-releases/exosome-diagnostics-and-qiagen-expand-collaboration-develop-non-invasive [Accessed 31 Aug. 2017].
 Exosome Diagnostics Completes $30 Million Series C Financing. [online] GlobeNewswire News Room. Available at: https://globenewswire.com/news-release/2017/07/24/1056075/0/en/Exosome-Diagnostics-Completes-30-Million-Series-C-Financing.html [Accessed 31 Aug. 2017].
 GEN. (2017). Exosome Startup Launched by MD Anderson, 2 VC Firms with $80M+ | GEN. [online] Available at: http://www.genengnews.com/gen-news-highlights/exosome-startup-launched-by-md-anderson-2-vc-firms-with-80m/81251985 [Accessed 28 Aug. 2017].
 ExoCoBio Inc. attracts Series A investment of US$11 million. [online] PRWeb. Available at: http://www.prweb.com/releases/2017/04/prweb14284662.htm [Accessed 3 Sep. 2017].